Beyond Phages: Exploring Endolysins as Key Players in the Future of Antibacterial Therapeutics

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Bacteriophages".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 141

Special Issue Editor


E-Mail Website
Guest Editor
Instituto de Productos Lácteos de Asturias (IPLA-CSIC), Paseo Río Linares, sn, 33300 Villaviciosa, Asturias, Spain
Interests: bacteriophages; endolysins; phage therapy; biocontrol; Staphylococcus aureus; biofilms
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Phage endolysins are enzymes produced by bacteriophages (viruses that infect bacteria) during the final stages of the lytic cycle. These enzymes play a crucial role in the phage lifecycle by breaking down the bacterial cell wall from the inside, leading to the release of newly formed phage particles. Endolysins have gained attention for their potential as novel antimicrobials due to notable advantages, such as their specificity, rapid bactericidal action, synergy with antibiotics, and low likelihood of resistance. Research into the development and application of endolysins as antimicrobials is ongoing, and they hold promise as a valuable addition to the arsenal of antimicrobial strategies, particularly in the context of addressing antibiotic-resistant bacterial infections. The use of endolysins in phage therapy still needs some research to address challenges, optimize treatment protocols, and gather robust clinical evidence. Some therapeutic issues are related to dosing, administration routes, bioavailability, immunogenicity, and ensuring safety and efficacy across diverse patient populations. This Special Issue will explore recent research supporting, but not limited to, the following: (1) clinical evidence on the efficacy and safety of endolysins in humans, (2) progress in developing regulatory frameworks and standards for approval (production, quality control, and clinical use), and (3) development in scaling up the production for commercial use and addressing associated cost.

Dr. Pilar García Suárez
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • endolysins
  • bacteriophages
  • phage therapy
  • antimicrobial resistance
  • clinical trials
  • regulatory framework

Published Papers

This special issue is now open for submission.
Back to TopTop